ArticleIn vivo (Athens, Greece)
Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Prevalence of Malnutrition and Early-Stage Age-Related Macular Degeneration: Using Three Nutritional Scoring Systems.Translational vision science & technology · 2025Article
- The Combined Therapeutic Effect of Lenvatinib and ADI-PEG 20 in Advanced Hepatocellular Carcinoma: A Case Report.In vivo (Athens, Greece)Article
- Modified Subtraction Technique for the Middle Hepatic Vein Tributary and Glissonean Pedicle in Right Lobe Graft Procurement.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimSeveral studies have reported the association between lenvatinib (LEN) treatment and nutritional indices. However, no study has used multiple nutritional indices or reported their changes during treatment. This study aimed to clarify the association between LEN treatment and nutritional status. PATIENTS AND
methodsPatients with hepatocellular carcinoma (n=103) treated with LEN were divided into two groups, namely normal and poor nutritional groups, using the Controlling Nutritional Status (CONUT) score, Onodera-Prognostic Nutritional Index (O-PNI), modified Glasgow Prognostic Score (mGPS), and Geriatric Nutritional Risk Index (GNRI). Treatment retention rates were then compared between the two groups. Additionally, changes in nutritional indices from the start of treatment to the end of the observation period or treatment were analyzed to determine their relationship with treatment continuation.
resultsPatients with normal nutrition according to the CONUT score, O-PNI, mGPS, and GNRI had a significantly higher rate of treatment retention than those with poor nutrition. Furthermore, both a normal CONUT score and mGPS indicated a lower likelihood of discontinuation due to adverse events. Patients in whom treatment was continued were significantly more likely to maintain or improve their CONUT score.
conclusionMaintaining or restoring a normal nutritional status is important to ensure continued treatment with LEN. Both the combination of the CONUT score and mGPS at the start of LEN treatment, and the CONUT score during treatment, are useful indicators of nutritional status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.